341 related articles for article (PubMed ID: 26379820)
21. [Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].
Znoyko OO; Klimova EA; Maevskaya MV; Shuldyakov АA; Linkova YN; Morozova MA
Ter Arkh; 2016; 88(11):156-162. PubMed ID: 28635836
[TBL] [Abstract][Full Text] [Related]
22. Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.
Dixit VK; Ghosh JK; Lamtha SC; Kaushik P; Goyal SK; Behera MK; Singh N; Jain AK
J Clin Exp Hepatol; 2014 Jun; 4(2):101-5. PubMed ID: 25755547
[TBL] [Abstract][Full Text] [Related]
23. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
Wu SH; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2019 Mar; 82(3):186-190. PubMed ID: 30908411
[TBL] [Abstract][Full Text] [Related]
24. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
25. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.
Acharya SK; Sreenivas V; Gupta SD; Kumar S; Chawla YK; Tandon A; Habeeb A; Kar P; Chowdhury A; Choudhuri G; Sarin SK; Amarapurkar D; Arankalle V; Gupte MD; Gupta S; Mukherjee D; Seth D; Goyal R; Tandon BN
J Clin Exp Hepatol; 2012 Mar; 2(1):10-8. PubMed ID: 25755401
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
[TBL] [Abstract][Full Text] [Related]
28. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
Božić M; Bojović K; Fabri M; Nožić D; Trkulja B; Milošević I
Srp Arh Celok Lek; 2012; 140(7-8):448-55. PubMed ID: 23092029
[TBL] [Abstract][Full Text] [Related]
30. Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus.
Todorovska B; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Popova-Jovanovska R; Grivceva-Stardelova K; Licoska-Josifovic F; Andreevski V; Curakova-Ristovska E; Joksimovic N
Open Access Maced J Med Sci; 2019 May; 7(10):1641-1648. PubMed ID: 31210815
[TBL] [Abstract][Full Text] [Related]
31. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin.
Atsukawa M; Tsubota A; Shimada N; Yoshizawa K; Abe H; Asano T; Ohkubo Y; Araki M; Ikegami T; Okubo T; Kondo C; Osada Y; Nakatsuka K; Chuganji Y; Matsuzaki Y; Iwakiri K; Aizawa Y
Hepatol Res; 2016 Mar; 46(5):450-8. PubMed ID: 26289410
[TBL] [Abstract][Full Text] [Related]
32. Ribavirin in the treatment of chronic hepatitis C.
Martin P; Jensen DM
J Gastroenterol Hepatol; 2008 Jun; 23(6):844-55. PubMed ID: 18565019
[TBL] [Abstract][Full Text] [Related]
33. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
Kowala-Piaskowska A; Mozer-Lisewska I; Figlerowicz M; Słuzewski W
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1095-103. PubMed ID: 17724740
[TBL] [Abstract][Full Text] [Related]
34. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
35. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
36. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
[TBL] [Abstract][Full Text] [Related]
37. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
Petta S; Cammà C; Scazzone C; Tripodo C; Di Marco V; Bono A; Cabibi D; Licata G; Porcasi R; Marchesini G; Craxí A
Hepatology; 2010 Apr; 51(4):1158-67. PubMed ID: 20162613
[TBL] [Abstract][Full Text] [Related]
38. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
Annemans L; Warie H; Nechelput M; Peraux B
Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
[TBL] [Abstract][Full Text] [Related]
39. [Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
Porubcin S; Schréter I; Kristian P; Pellová A
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):74-8. PubMed ID: 18756437
[TBL] [Abstract][Full Text] [Related]
40. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
Fujita N; Sugimoto R; Motonishi S; Tomosugi N; Tanaka H; Takeo M; Iwasa M; Kobayashi Y; Hayashi H; Kaito M; Takei Y
J Hepatol; 2008 Nov; 49(5):702-10. PubMed ID: 18620776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
